title: Evaluation of the immunity activity of glycyrrhizin in AR mice.
abstract: In this study, we evaluated effect of glycyrrhizin on immunity function in allergic rhinitis (AR) mice. The AR mice model were induced by dripping ovalbumin in physiological saline (2 mg mL⁻¹, 10 μL) into the bilateral nasal cavities using a micropipette. After the AR model was induced, mice were randomly divided into six groups: the normal control, model, lycopene 20 mg kg⁻¹ (as positive control drug) group, and glycyrrhizin 10, 20, 30 mg kg⁻¹ groups. After the sensitization day 14, lycopene (20 mg/kg BW) and glycyrrhizin (10, 20 and 30 mg/kg BW) were given orally for 20 days once a day. Mice in the normal control and model groups were given saline orally once a day for 20 days. Results showed that glycyrrhizin treatment could dose-dependently significantly reduce blood immunoglobulin E (IgE), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), nitrous oxide (NO), tumor necrosis factor-alpha (TNF-α) levels and nitrous oxide synthase (NOS) activity and enhance blood immunoglobulin A (IgA), immunoglobulin G (IgG), immunoglobulin M (IgM), interleukin-2 (IL-2) and interleukin-12 (IL-12) levels in AR mice. Furthermore, glycyrrhizin treatment could dose-dependently significantly enhance acetylcholinesterase (AchE) activity and reduce substance P (SP) level in peripheral blood and nasal mucosa of AR mice. We conclude that glycyrrhizin can improve immunity function in AR mice, suggesting a potential drug for the prevention and therapy of AR.
authors.affiliation: Ear-Nose-Throat Department of the 1st Hospital Associated to the ShiHeZi University, ShiHeZi City 832008, XinJiang, China. lixlsdoc158@yahoo.com.cn
authors.forename: Xiao-Lan
authors.initials: XL
authors.lastname: Li
authors.forename: Ai-Guo
authors.initials: AG
authors.lastname: Zhou
mesh_terms: D000110:Acetylcholinesterase / Q000378:metabolism; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use; D019695:Glycyrrhizic Acid / Q000494:pharmacology* / Q000627:therapeutic use; D007136:Immunoglobulins / Q000097:blood; D007378:Interleukins / Q000097:blood; D008297:Male; D051379:Mice; D009297:Nasal Mucosa / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D009569:Nitric Oxide / Q000097:blood; D019001:Nitric Oxide Synthase / Q000097:blood; D010047:Ovalbumin; D011897:Random Allocation; D051381:Rats; D012221:Rhinitis, Allergic, Perennial / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy / Q000276:immunology*; D013373:Substance P / Q000097:blood / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D000893:Anti-Inflammatory Agents; D007136:Immunoglobulins; D007378:Interleukins; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide; D013373:Substance P; D019695:Glycyrrhizic Acid; D010047:Ovalbumin; D019001:Nitric Oxide Synthase; D000110:Acetylcholinesterase